PMID- 37652522
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 37
IP  - 5
DP  - 2023 Sep-Oct
TI  - Cetuximab Plus Concurrent Radiotherapy in Patients With Nasopharyngeal Carcinoma.
PG  - 2224-2228
LID - 10.21873/invivo.13323 [doi]
AB  - BACKGROUND/AIM: Several reports have evaluated the efficacy and safety of 
      concurrent radiotherapy with cetuximab (BRT) in patients with nasopharyngeal 
      carcinoma (NPC). Combination therapy with cetuximab can be a treatment option for 
      NPC. Although clinical data regarding the efficacy and safety of BRT without 
      induction chemotherapy (ICT) or adjuvant chemotherapy is essential for the 
      development of new therapeutic strategies, such data are rarely reported. 
      PATIENTS AND METHODS: We retrospectively investigated a series of patients with 
      NPC treated in our institution to evaluate the efficacy and safety of BRT. Eleven 
      patients with newly diagnosed NPC were identified from an inpatient database from 
      July 2015 to April 2018. Seven patients who received BRT were reviewed. RESULTS: 
      All patients completed BRT without cessation of treatment. Six (85.7%) patients 
      achieved a complete response and one (14.3%) achieved stable disease. The 
      response rate was 85.7%. All patients with </=T3 disease achieved a complete 
      response. Both patients with T3 disease developed local recurrence, and one of 
      the four patients with T1-2 disease developed distant metastases. The 1- and 
      3-year overall survival rates were 85.7% and 47.6%, respectively. The most common 
      adverse events (AEs) were pharyngeal mucositis (100%), radiation dermatitis 
      (100%), anorexia (28.6%), weight loss (28.6%), acneiform rash (28.6%), and dry 
      mouth (28.6%). Grade 3 AEs were pharyngeal mucositis (42.9%), radiation 
      dermatitis (28.6%), and anorexia (14.3%). No grade 4/5 AEs were observed. 
      CONCLUSION: BRT for NPC was tolerable, but our findings suggest that BRT without 
      induction chemotherapy or adjuvant chemotherapy is insufficient at least for >/=T3 
      disease.
CI  - Copyright (c) 2023, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Yamauchi, Moriyasu
AU  - Yamauchi M
AD  - Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of 
      Medicine, Nabeshima, Japan yamamori@cc.saga-u.ac.jp.
FAU - Sato, Yuki
AU  - Sato Y
AD  - Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of 
      Medicine, Nabeshima, Japan.
FAU - Ishida, Tomoya
AU  - Ishida T
AD  - Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of 
      Medicine, Nabeshima, Japan.
FAU - Minesaki, Akimichi
AU  - Minesaki A
AD  - Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of 
      Medicine, Nabeshima, Japan.
FAU - Shimazaki, Eriko
AU  - Shimazaki E
AD  - Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of 
      Medicine, Nabeshima, Japan.
FAU - Kuratomi, Yuichiro
AU  - Kuratomi Y
AD  - Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of 
      Medicine, Nabeshima, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - PQX0D8J21J (Cetuximab)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Humans
MH  - Cetuximab/adverse effects
MH  - Nasopharyngeal Carcinoma
MH  - *Mucositis/drug therapy
MH  - Retrospective Studies
MH  - Anorexia/etiology
MH  - *Nasopharyngeal Neoplasms/drug therapy/pathology
MH  - *Radiodermatitis/etiology
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Cisplatin
MH  - Chemoradiotherapy/adverse effects
PMC - PMC10500510
OTO - NOTNLM
OT  - BRT
OT  - Cetuximab
OT  - nasopharyngeal carcinoma
OT  - radiotherapy
COIS- The Authors have no conflicts of interest to disclose with respect to the 
      publication of this paper.
EDAT- 2023/09/01 00:41
MHDA- 2023/09/01 00:42
PMCR- 2023/09/03
CRDT- 2023/08/31 20:38
PHST- 2023/05/14 00:00 [received]
PHST- 2023/06/03 00:00 [revised]
PHST- 2023/06/06 00:00 [accepted]
PHST- 2023/09/01 00:42 [medline]
PHST- 2023/09/01 00:41 [pubmed]
PHST- 2023/08/31 20:38 [entrez]
PHST- 2023/09/03 00:00 [pmc-release]
AID - 37/5/2224 [pii]
AID - 10.21873/invivo.13323 [doi]
PST - ppublish
SO  - In Vivo. 2023 Sep-Oct;37(5):2224-2228. doi: 10.21873/invivo.13323.